The United States may soon add another weapon to the arsenal.

Johnson and Johnson announced on Friday that it's single dose vaccine was 66% effective in preventing Cove in 19 in a large global try alot against multiple variants in the study of nearly 44,000 volunteers across three continents, the level of protection against moderate and severe Cove in 19 varied from 72% in the United States to 66% in Latin America but just 57% in South Africa, where a particularly worrying variant has been circulating.

The U.

S found its first cases of the South African variant in the state of South Carolina this week.

The Globe is in an urgent race, trying to vaccinate as many people as possible before more of these variants can spread further and others can emerge cut down on global cases and you cut down on the chance for new, dangerous mutations, Top US infectious disease specialist Anthony Fauci.

This is a wake up call to all of us that we will be dealing as the virus uses its devices to evade pressure, particularly immunological pressure that we will continue to see the evolution of mutants.

So we that means that we as a government, the companies, all of us that are in this together will have to be nibbled.

This all tells us that it is an incentive to do what we've been saying all along to vaccinate as many people as we can as quickly as we possibly can.

Johnson and Johnson plans to seek emergency use authorization from the U.

S.

Food and Drug Administration next week.

It has said it plans to deliver one billion doses of the vaccine globally in 2021 which it will make in the United States, Europe, South Africa and India.

Unlike the Pfizer and Madonna vaccines, J and J's does not require a second shot weeks after the first.